Fatty Acid Amide Hydrolase (FAAH) Inhibitor -Pipeline Insight, 2018

Fatty Acid Amide Hydrolase (FAAH) Inhibitor -Pipeline Insight, 2018

  • Pages: 60
  • Geography: Global
  • Delivery Timeline: 48 hrs
  • Publication: Jan, 2018
  • SKU: DIMA0200
  • Single User License
    (20% Off)
    $1,250.00
    $1000
  • Site License
    (30% Off)
    $2,500.00
    $1750
  • Global License
    (40% Off)
    $4,000.00
    $2400
Request Sample

Name*  
Email ID*  
Mobile*  
Company*  
Country*  
Zip Code*  
Address*  
Message*  
X

Request Sample Pages

Request Before Buy
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Inquire Before Buy

Send Friend
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Send to Friend

"Fatty Acid Amide Hydrolase (FAAH) Inhibitors- Pipeline Insights, 2018" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across Fatty Acid Amide Hydrolase (FAAH) Inhibitor. A detailed picture of the pipeline landscape is provided with summation of data from multiple sources with complete analysis by development stage, mechanism of action, route of administration and molecule type. This report provides detailed analysis of 5+ active products with more than 5 companies involved. Two of the key players include PF-04457845 of Spring Works Therapeutics and JNJ-42165279 of Janssen. 
Products covered by Phase

• Phase II 

• Pre-clinical 

• Inactive (Dormant and Discontinued)

Overview of pipeline development activities for Fatty Acid Amide Hydrolase (FAAH) Inhibitors 
Pipeline analysis of therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and pre-clinical results, designations, collaborations & licensing deals, grants, technology and patent details.
Therapeutic segmentation of products for Fatty Acid Amide Hydrolase (FAAH) Inhibitors
The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this mechanism. 
Methodology
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. 
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
Scope of the report

• Provides an overview of therapeutic pipeline activity for Fatty Acid Amide Hydrolase (FAAH) Inhibitors across the complete product development cycle including all clinical and non-clinical stages

• It comprises of detailed profiles of Fatty Acid Amide Hydrolase (FAAH) Inhibitors therapeutic products with key coverage of developmental activities including licensing & collaboration deals, patents issued, designations, technologies and chemical information

• Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration

• Coverage of dormant and discontinued pipeline projects across Fatty Acid Amide Hydrolase (FAAH) Inhibitors 
Reasons to Buy

• Establish a comprehensive understanding of the current pipeline scenario across Fatty Acid Amide Hydrolase (FAAH) Inhibitors to formulate effective R&D strategies

• Assess challenges and opportunities that influence Fatty Acid Amide Hydrolase (FAAH) Inhibitors R&D

• Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage

• Identify the relationship between the products and use it for target finding, drug repurposing, and precision medicine

• Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Fatty Acid Amide Hydrolase (FAAH) Inhibitors to enhance and expand business potential and scope 

• Our extensive domain knowledge on therapy areas support the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive and discontinued drugs

Overview
Introduction
Oleamide and Anandamide
Function of Fatty acid amide hydrolase (FAAH)
Structure of FAAH
Mechanism of Action of FAAH
Fatty acid amide hydrolase (FAAH) Inhibitor
Future Scope for FAAH Inhibitor
Emergence of FAAH Inhibitors
Pipeline Therapeutics (Active Products)
Pipeline Therapeutics (Inactive Products)
Comparative Analysis
Mid Stage Products (Phase II)
Comparative Analysis
JNJ 42165279: Janssen
Product Description
Research and Development
The list continues…..
Early Stage Products (Phase I)
Comparative Analysis
Pre-clinical and Discovery Stage Products
Comparative Analysis
Therapeutic Assessment: Active Products
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Inactive Products
Comparative Analysis
Appendix

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

List of Tables
Table 1: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Table 2: Mid Stage Products (Phase II)
Table 3: Early Stage Products (Phase I)
Table 4: Pre-clinical and Discovery Stage Products
Table 5: Assessment by Stage and Product Type
Table 6: Assessment by Route of Administration
Table 7: Assessment by Stage and Route of Administration
Table 8: Assessment by Molecule Type
Table 9: Assessment by Stage and Molecule Type
Table 10: Inactive Products

 

List of Figures
Figure 1: Mechanism of Fatty Acid Amide Hydrolase
Figure 2: Structure of Oleamide and Anandamide
Figure 3: Function of FAAH
Figure 4: Function of FAAH
Figure 5: Total Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Stage and Product Type
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Inactive Products

 

Key Companies
Speak to Analyst
Name*  
Email ID*  
Mobile*  
Company*  
Country*  
Zip Code*  
Specific Filed of Interest*  
X

Speak to Analyst

+1(919)321-6187

Related Reports

Contact Us

Phone

India: +91-11-45689769, +91-9650213330

Email

info@delveinsight.com

Address

New Delhi-110075, India

Address

304 S. Jones Blvd #2432, Las Vegas NV 89107

Phone

Outside India: +1(919)321-6187

Latest Tweets

Copyright © 2018 Delveinsight.